International Zinc Association Partners With Pharmanova to Save Children in Zambia
21.1.2026 09:00:00 CET | Business Wire | Press Release
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA), has announced a new partnership with leading Zambian pharmaceutical manufacturer Pharmanova Zambia Limited to expand access to life‑saving zinc treatments for children across Zambia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121178091/en/
Life-saving zinc-supplementation and oral rehydration salts kits are proactively distributed to Zambian children through the works of the International Zinc Association, Pharmanova, and the Zambian Ministries of Health and Education.
The collaboration was formally celebrated during a ceremony in Lusaka with the Zambian Ministry of Health, Pharmanova Zambia Limited, and IZA represented by Environment Health & Sustainability Director Dr. Eric Van Genderen.
IZA and Pharmanova have united in an effort to scale up treatment for childhood diarrhea using zinc, an essential micronutrient that strengthens immune systems and reduces the severity and duration of diarrheal disease. The need is urgent: more than 30% of Zambia’s population is zinc‑deficient, leaving children especially vulnerable to diarrhea, pneumonia, and malaria. Globally, 116,000 children are estimated to die from zinc deficiency related issues every year.
Through this partnership, every dollar donated to Zinc Saves Kids will directly support the distribution of Kit Yamoyo, the “Kit of Life,” which includes oral rehydration salts (ORS) and a ten‑day supply of zinc tablets. Zinc and ORS are recommended by the World Health Organization for the treatment of diarrhea. Each kit provides a complete treatment for diarrhea and helps prevent future illness.
“IZA is thrilled to work with Pharmanova to address zinc deficiency, which weakens the immune systems of at‑risk children and leaves them vulnerable to diarrhea, pneumonia, and malaria,” said Dr. Van Genderen. “Zinc is critical to healthy mental and physical development, and this partnership is an important step toward improving child health in Zambia.”
The first tranche of donations already has supplied 50,000 zinc and oral rehydration kits to Zambian children. Distribution is being conducted through the government’s Healthy Learners program, which operates in schools nationwide and focuses on reaching rural and underserved communities.
Pharmanova, established in 1980, developed Kit Yamoyo to combat childhood diarrhea and has previously partnered with agencies including USAID and UNICEF to expand access to essential medicines.
“There is a great need for Kit Yamoyo across Zambia and beyond, so we are pleased to have the opportunity to work with the International Zinc Association, which has a long history of addressing zinc deficiency worldwide,” said Mohammed Umar, CEO of Pharmanova. “We envision a long and fruitful partnership with Zinc Saves Kids.”
Launched in 2010, Zinc Saves Kids works to raise awareness of global zinc deficiency and supports programs focused on supplementation, food fortification, and treatment. The partnership with Pharmanova marks a significant expansion of the initiative’s reach, which has previously raised more than $4 million to provide life-saving research, education, and treatment related to zinc.
About the International Zinc Association
The International Zinc Association (IZA) is the only organization dedicated exclusively to the interests of zinc and its users. As the voice of the global zinc industry, IZA provides global leadership, coordination, and value on strategic issues for the zinc industry, including market development, license to operate, communications, and sustainability.
About Pharmanova Zambia Limited
Pharmanova Zambia Limited has been at the forefront of the Zambian pharmaceutical manufacturing industry since 1980, providing a diverse range of essential products aimed at enhancing health, hygiene, and overall well-being for Zambia and the region. Pharmanova operates three manufacturing sites strategically located in Lusaka, the capital city of Zambia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260121178091/en/
Contacts
Media Contact for International Zinc Association
Tanya Correa
tcorrea@zinc.org
1-202-487-4534
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press Release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press Release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press Release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press Release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom